Professor Christopher Marshall
Prosiectau fel Prif Ymchwiliwr
- Evaluation of CT26 and 4T1 tumour and metastases targeting of RAW 264.7 (labelled with [89Zr]oxinate-4 and 89zr-DFO-derritin) using PET (01.08.2017 - 31.07.2019)
- Fees - Andrew Fenwick (01.10.2014 - 30.09.2019)
- In vivo imaging of Tau distribution in the brain (01.01.2016 - 31.03.2017)
- Medical Physics expert advice and support (01.01.2019 - 31.12.2020)
- Optimization of scanning with CZT gamma cameras to improve the detection of metastatic spread to the bone in a range of cancers (01.07.2019 - 30.06.2024)
Prosiectau fel Cyd-Ymchwiliwr
- 18F-Gemcitabine as diagnostic tool in personalised chemotherapy (01.06.2017 - 31.10.2018)
- IDEA - Integrated DEmentiA research environment (01.04.2015 - 31.03.2016)
- Improving outcomes for patients with pituitary disease: advancing therapeutics and diagnostics using electronic health records and molecular imaging (01.12.2021 - 31.07.2024)
- Longitudinal monitoring of T lymphocyte migration in vivo (01.08.2015 - 31.08.2018)
- Multi-Modal theranostics (MMTs) - towards personalized cancer therapies (01.07.2014 - 30.04.2016)